Suspended: Bebtelovimab Replacement Requests in HPOP
November 30, 2022, the U.S. Food and Drug Administration (FDA) announced that bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1., according to data included in the
Health Care Provider Fact Sheet. Following the FDA’s Announcement, ASPR paused the fulfillment of any pending requests under the Bebtelovimab Product Replacement Initiative.
Information for Providers
Health Partner Ordering Portal (HPOP) is an ordering portal for allocating and/or requesting COVID-19 therapeutic products. HPOP is used to order U.S. Government (USG) procured COVID-19 therapeutic products.
Bebtelovimab Product Replacement Initiative
On September 23, 2022, the U.S. Department of Health and Human Services (HHS) announced a new effort to help uninsured and underinsured Americans access the COVID-19 monoclonal antibody treatment bebtelovimab following its transition to the commercial market.
On November 30, 2022, ASPR paused the fulfillment of any pending requests under the Bebtelovimab Product Replacement Initiative following FDA’s announcement that the bebtelovimab is not currently authorized for emergency use in the U.S.
Help Desk and Support
CARS Helpdesk should be the first stop for all issues related to HPOP Therapeutics:
CARS Help Desk will escalate issues to the HPOP Therapeutics Help Desk.
For general bebtelovimab product replacement initiative questions contact